Verstovsek, Srdan
Mesa, Ruben A.
Livingston, Robert A.
Hu, Wilson
Mascarenhas, John
Funding for this research was provided by:
Incyte
Article History
Received: 27 April 2023
Accepted: 22 June 2023
First Online: 27 July 2023
Declarations
:
: Not applicable.
: Srdan Verstovsek received research support from AstraZeneca, Blueprints Medicines Corp., Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte Corporation, ItalPharma, Novartis, NS Pharma, PharmaEssentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology; and is a paid consultant for Celgene, Incyte, Novartis, and Sierra Oncology. Ruben A. Mesa has served as a consultant for AOP, Incyte, La Jolla Pharma, Novartis, and Sierra; and has received research funding from AbbVie, Celgene, CTI, Genentech, Gilead, Incyte, and Sierra. Robert Livingston and Wilson Hu are employees and shareholders of Incyte. John Mascarenhas received consulting fees from AbbVie, Bristol Myers Squibb, Celgene, Constellation, CTI Bio, Galecto, Geron, GlaxoSmithKline, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia, Sierra Oncology, and Roche; and research funding paid to the institution from AbbVie, Bristol Myers Squibb, CTI Bio, Geron, Incyte, Kartos, Novartis, PharmaEssentia, and Roche.